Kura Oncology (KURA) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MoonLake Immunotherapeutics (MLTX) has outperformed Kura Oncology (KURA) over the past year, gaining 16.3% versus a gain of 4.4%. Over five years, MLTX leads with a +6.7% price change compared with -41.6% for KURA. Kura Oncology is the larger company by market cap ($943.0 million vs $920.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | MLTX |
|---|---|---|
| Share price | $10.60 | $10.82 |
| Market cap | $942.98M | $920.85M |
| 1-day change | +0.76% | +2.27% |
| YTD return | +1.25% | -19.73% |
| 1-year return | +4.37% | +16.26% |
| 5-year return | -41.62% | +6.65% |
| EPS (TTM) | $-3.37 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.90 | $23.29 |
| 52-week low | $7.36 | $8.80 |
| Distance from 52-week high | -23.74% | -53.54% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +200.47% | +163.77% |
| Average volume | 1.77M | 1.47M |
| Shares outstanding | 88.96M | 85.11M |
| Employees | 260 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MLTX has outperformed KURA by 11.9 percentage points over the past year.
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
KURA vs MLTX FAQ
Which is bigger, Kura Oncology or MoonLake Immunotherapeutics?
Kura Oncology (KURA) is larger, with a market capitalization of $942.98M compared with $920.85M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, KURA or MLTX?
MLTX returned +16.26% over the past 12 months, compared with +4.37% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.